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Background: Rare, recurrent genomic imbalances facilitate the association of genotype with abnormalities at the
“whole body” level. However, at the cellular level, the functional consequences of recurrent genomic abnormalities
and how they can be linked to the phenotype are much less investigated.
Method and results: We report an example of a functional analysis of two genes from a new, overlapping
microdeletion of 2p13.2 region (from 72,140,702-72,924,626). The subjects shared intellectual disability (ID), language
delay, hyperactivity, facial asymmetry, ear malformations, and vertebral and/or craniofacial abnormalities. The
overlapping region included two genes, EXOC6B and CYP26B1, which are involved in exocytosis/Notch signaling
and retinoic acid (RA) metabolism, respectively, and are of critical importance for early morphogenesis, symmetry as
well as craniofacial, skeleton and brain development. The abnormal function of EXOC6B was documented in patient
lymphoblasts by its reduced expression and with perturbed expression of Notch signaling pathway genes HES1 and
RBPJ, previously noted to be the consequence of EXOC6B dysfunction in animal and cell line models. Similarly, the
function of CYP26B1 was affected by the deletion since the retinoic acid induced expression of this gene in patient
lymphoblasts was significantly lower compared to controls (8% of controls).
Conclusion: Haploinsufficiency of CYP26B1 and EXOC6B genes involved in retinoic acid and exocyst/Notch
signaling pathways, respectively, has not been reported previously in humans. The developmental anomalies and
phenotypic features of our subjects are in keeping with the dysfunction of these genes, considering their known
role. Documenting their dysfunction at the cellular level in patient cells enhanced our understanding of biological
processes which contribute to the clinical phenotype.
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Chromosomal abnormalities involving the 2p13 chromo-
somal region were detected previously in subjects with
developmental delay using traditional chromosome test-
ing [1,2]. Abnormal features present in at least 50% of
cases included abnormal head size/shape, nose, ears,
chest and vertebral, digital and genital anomalies. The
involvement of the CYP26B1 gene was suggested in a
subject with a de novo inversion involving 2p13 and
2q34, who had a Klippel-Fiel anomaly (vertebral fusion
of cervical spine), psychomotor retardation, speech limi-
tation, facial asymmetry, ear abnormalities, and scoliosis
[3,4]. Disruption of EXOC6B and its fusion with TNS3
from 7p12 due to a translocation t(2;7)(p13;p12), was con-
sidered to be a possible cause of the intellectual disability,
ADHD and congenital abnormalities (renal malformation,
microcephaly, long bone diaphyseal broadening) in a sub-
ject reported by Borsani et al. [5].
CYP26B1 (cytochrome P450, family 26, subfamily B,
polypeptide 1) is one of the three CYP26 gene isoforms
(CYP26B1, CYP26A1 and CYP26C1) which encode the
cytochrome-P450 enzymes that catabolize retinoic acid
(RA) [6]. RA is the principal active metabolite of vitamin
A and is an essential component of cell-cell signaling
during vertebrate organogenesis [7]. Too little or too
much RA causes the human malformation syndrome as-
sociated with vitamin A deficiency (VAD) or RA
embryopathy, which includes craniofacial (e.g. ears, eyes,
facial asymmetry), central nervous, musculoskeletal, and
urogenital abnormalities [8-12]. Homozygous knockout
of CYP26B1 in animals has been associated with postna-
tal mortality, abnormal craniofacial, limb and gonadal
development [13,14], while a conditional deletion (con-
trolled expression) of CYP26B1 resulted in a less severe
phenotype. The difference in the phenotypes was attrib-
uted to differing levels of activated retinoid signaling
[15]. Although deletions of the whole CYP26B1 gene
have not yet been reported in humans, homozygous
point mutations of CYP26B1 were reported in two
families, resulting in prenatal and early postnatal le-
thality, skeletal and craniofacial abnormalities, fusion
of long bones, calvarial bone hypoplasia and sutural
defects, resulting in craniostenosis and brachycephaly
[16]. CYP26B1 mutations in both families led to a sig-
nificantly attenuated ability to metabolize exogenously
applied retinoic acid, confirming the impact of dys-
function of this gene on RA metabolism. Previous
studies have shown that CYP26B1 is responsible for
ATRA (all-trans retinoic acid) clearance in several tis-
sues [17]. For example in T-cells, CYP26B1 is the only
CYP26 enzyme up-regulated by ATRA and its expression
regulates retinoic acid dependent signals in T-cells [18].
In addition, in many human cell lines CYP26B1 mRNA is
inducible by retinoic acid treatment while in rodentscyp26b1 expression correlates with dietary vitamin A
intake [19-22].
EXOC6B (exocyst complex component 6B) encodes a
protein homologous to Sec15 in Saccharomyces cervisiae.
It belongs to a multiprotein complex (exocyst) required
for targeted secretion (exocytosis) which is crucial for cell
polarity, growth and communication [23]. In Drosophila,
sec15 promotes Notch signaling, through specific vesicle
trafficking of delta ligand, and has a role in asymmetric
division of sensory precursors and neuronal fate deter-
mination [24]. Drosophila neurons with sec15 mutations
show loss of synaptic specificity and mislocalization of
proteins known to affect synaptic specificity in photore-
ceptors [25]. Recently, Guichard et al. showed reduced
transcription of Notch signaling effectors HES1 and RBPJ
in knockdown Drosophila sec15 and in a human brain
microendothelial cell line with abnormal EXOC6B func-
tion [26]. Notch signaling plays a pivotal role in the
regulation of many fundamental cellular processes, such
as acquisition of specific fates in context-dependent
manner, differentiation and lineage decisions during
embryonic development, neurogenesis, as well as mor-
phogenesis involving regulation of left-right asymmetry
[27,28]. Perturbations of the Notch pathway have been
reported in human developmental disorders which
demonstrate a variety of symptoms, including ID and/
or skeletal abnormalities (e.g. Allagile syndrome and
spondylocostal dysostosis [29,30]).
We report the first description of the clinical and
functional consequences of hemizygous deletion of the
two genes, CYP26B1 and EXOC6B, located in chromo-
some region 2p13, and which are respectively, involved
in retinoic acid and Notch signaling pathways of critical
importance to normal human fetal development.
Materials and methods
Whole genome array CGH analysis
Genomic DNA was extracted from peripheral blood using
the PUREGENE DNA Isolation Kits (Gentra, Minneapolis,
MN) for Subject 1 and Citogene® DNA isolation kit
(Citomed, Portugal) for Subject 2. For Subject 1, Agilent
105 K array (version 4.0, June 2006, Agilent Technolo-
gies, CA, USA) analysis was performed as previously de-
scribed.25 CNV selection was done by Agilent DNA
Analytics (version 3.5.14, Agilent Technologies) using the
ADM-2 algorithm (cutoff 6.0), followed by a filter to se-
lect regions with three or more adjacent probes and a
minimum average log2 ratio + 0.25 [31]. The deletion of
Subject 1 was de novo, as determined by FISH using
probe RP11-91 F23.
For Subject 2, the aCGH analysis was performed using
a CGH Agilent 180 K custom array design accessible
through the gene expression omnibus (GEO) accession
number GPL15397. Previously published protocol was
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across-array methodology described previously [33].
CGH data was analyzed using Nexus Copy Number 5.0
software with FASST Segmentation algorithm. The dele-
tion was determined to be de novo using the same array
for both parents.
For both cases, the array design, database consultation
and comparative analysis was performed using genome
build 36.1/HG18.
Functional studies
Immortalized EBV transformed lymphoblastoid cell lines
(LCL) from Subject 1 were cultured in RPMI media
containing 10% FBS, 50 units/mL penicillin, 50 μg/mL
streptomycin. Cells were maintained in a humidified 37°C
incubator with 5% CO2. Control cells were obtained from
healthy subjects, the majority of which aged 28–50 years.
RNA expression
Total RNA was extracted using an RNeasy Plus Mini kit
(Qiagen) from Subject 1-derived LCLs and whole blood
collected in Tempus tubes. Aliquots (~500 ng) of the
total RNA extracts prepared from were subsequently
reverse-transcribed into cDNA using GeneAmp Gold
RNA PCR Core Kit (Applied Biosystems).
The expression of EXOC6B and CYP26B1 was first
assessed in RNA extracted from control whole blood
and control LCLs by real-time qPCR using the ABI
PRISM 7300 Sequence Detection System (Perkin-Elmer
Applied Biosystems). The specific nucleotide sequences
for primers of EXOC6B and CYP26B1 were as follows:
EXOC6B Forward 5’-GAC CTC ATT GCC TTT CTT
CGT A-3’, Reverse 5’-CAA GCT GAC ATA CAC GCT
GT-3’(mapped to exons 18–19); CYP26B1 primer set 1;
Forward 5’-ACA CAG GGC AAG GAC TAC T-3’, Re-
verse: 5’-GCA TAG GCC GCA AAG ATC A-3’(mapped
to exon 4–5); CYP26B1 primer set 2: Forward: 5’-CTA
CCT GGA CTG CGT CAT CA-3’, Reverse: 5’-CCC
GGA TGC TAT ACA TGA CA-3’ (mapped to exon 5–6).
EXOC6B had a detectable transcript, while no transcript
was detected with CYP26B1 primers for exons 4–5 and
exons 5–6 in control whole blood, nor transformed
lymphoblasts.
Real-time qPCR was performed for EXOC6B and its
downstream genes HES1 and RBPJ using SYBR® Green
PCR Master Mix (Applied Biological Materials Inc). Pri-
mer sequences were as follows: HES1 Forward: 5’-GAG
CAC AGA AAG TCA TCA AAG C-3’ (mapped to
exons 1–3), Reverse: 5’-TTC CAG AAT GTC CGC CTT
C-3’; RBPJ Forward: 5’-GGG ATA GGA AAT AGT GAC
CAA GA-3’, reverse: 5’-GTG CTT TCG CTT GTC
TGA GT-3’ (mapped to exons 7–8).
Quantification of expression level of EXOC6B, HES1
and RBPJ was performed in comparison to actin. AllPCR reactions were performed in triplicate, with the
mean of 2-ΔΔCt values [34] being used to determine
mRNA levels for Subject 1 in comparison to the mean
expression level for three controls. Significance was cal-
culated using the Student’s t test (VassarState Statistical
Computation website). Values were considered statisti-
cally significant with a p-value of <0.05.
Protein expression
LCLs were washed three times in PBS and incubated in
1 mL RIPA buffer (Thermo Scientific, USA), supplemented
with Halt Phosphatase Inhibitor Cocktail (Thermo Scien-
tific, USA) for 15 minutes on ice. Cell lysates were
centrifuged at 10,000 × g for 15 minutes at 4°C, and
the supernatants were used for Western blotting. Cell
lysate protein concentrations were determined using a
DC™ Protein Assay (BioRad laboratories, USA). Western
blots containing cell-lysate aliquots (~30 μg) were pre-
pared and immunoblotted using a polyclonal antibody
directed against human RBPJ or a monoclonal anti-
body against human HES1 (Abcam, Cambrige, MA, USA).
Three antibodies against human EXOC6B were tested in
this study (Sec15B(C-14) (goat polycolonal antibody):sc-
34375, Santa Cruz Biotechnology,Inc. Anti-EXOC6B anti-
body (rabbit polycolonal antibody): ab116383, Abcam Inc.
Anti-EXOC6B antibody (mouse polycolonal antibody):
H00023233-B01P, Novus Biologicals) but did not provide
a clear or visible band at the expected size, amenable to
interpretation. To standardize the amounts of protein
loaded into each lane, the blots were reprobed with a
monoclonal antibody directed against human β-actin
(NovusBiologicals, Littleton, USA). The ECL Western
Blotting system was used to detect the amount of each
antibody bound to antigen and the resultant photographic
films were analyzed by UV densitometry (GE Healthcare
Life Sciences, Pittsburgh, USA). The absorbance values
obtained for HES1 and RBPJ were then normalized relative
to the corresponding β-actin absorbance value. The aver-
age of HES1 or RBPJ protein expression was obtained from
three independent replicates from the Subject and the con-
trol samples. P values for two tailed Student test were con-
sidered statistically significant if <0.05.
CYP26B1 expression upon ATRA induction
Cells from seven control subjects (aged 2–42 years) and
Subject 1 were plated in 6-well plates at a density of
400,000 cells/mL in 3 mL and treated in triplicate with
1 μM all-trans retinoic acid (ATRA) or an equal volume
of vehicle (ethanol) in triplicate and incubated in the
dark for 72 hours. Following treatment, cells were
pelleted and resuspended in 1 mL Tri-Reagent Solution
(Life Technologies, Grand Island, NY) followed by re-
peated pipetting to lyse the cells. RNA was then iso-
lated according to manufacturers instructions and RNA
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2000c spectrophotometer (Thermo Scientific, Waltham,
MA) by measuring the absorbance at 260 nm and
280 nm. Complimentary DNA (cDNA) was generated
from 1 μg total RNA by reverse transcription using the
TaqMan reverse transcription reagents kit (Life Tech-
nologies, Grand Island, NY), as previously described
[17,35]. TaqMan Gene Expression Master Mix, PCR
primers, and fluorescent probes were obtained from Ap-
plied Biosystems (Life Technologies, Grand Island, NY).
Probes were labelled with the 5’ reporter dye FAM
(CYP26A1 and CYP26B1) or VIC (GAPDH). Primer
probe pairs used were: CYP26A1 (Hs00219866_m1),
CYP26B1 (Hs00175627_m1), and the endogenous con-
trol GAPDH (RefSeq: NM_002046.3). Quantitative real-
time PCR was conducted on a StepOnePlus Real-Time
PCR instrument (Applied Biosystems, Foster City, CA)
as previously described [17,35]. The fold-increase in
CYP26A1 and CYP26B1 mRNA was calculated using
the ΔΔCt method (fold difference = 2
-ΔΔCt) by compar-
ing the ATRA-treated cells to the vehicle treated con-
trols. Differences between controls and patient were
tested by t-test using GraphPad Prism 5.0. Values werea
b c
B. Subject 2
A. Subject 1
a b
Figure 1 Clinical presentation of Subject 1 and Subject 2. A. Subject 1
asymmetry, right facial nerve palsy, dysplastic and prominent ears. By age
a) asymmetry of the jaw, b) left ear with thick helix, c) right ear (post surger
d) hands with slightly tapering fingers and e) normal body proportions exceconsidered statistically significant with a p-value <0.05.
Grubb’s test was used to determine if any of the sub-
jects met the criteria of an outlier.
The use of tissues was approved by the Committee for
Ethical Review of Research involving Human Subjects,
University of British Columbia. Written informed con-
sent was obtained from the patients’ parents for the pub-
lication of this report and any accompanying images.
Results
Clinical description
Subject 1
This male was seen by a geneticist as a neonate because
of dysmorphic features, including an asymmetric crying
face with a right facial nerve paralysis, a dysplastic right ear,
brachycephaly (Figures 1 and 2) and mild contractures of
the knees and elbows (which disappeared by five months).
The pregnancy was complicated by maternal nausea and
vomiting, with only a five pound maternal weight gain.
Birth weight was on the 10th centile. A 2 mm secundum
atrial septal defect closed in early infancy. His parents are
not consanguineous. A paternal great-uncle has intellectual
disability while another paternal great-uncle’s adult son hasd
d e
c
at age 2, 7, and 13 (a-c), demonstrating the facial appearance, with
13, the right ear was surgically corrected. B. Subject 2 demonstrating
y): small, dysplastic, cup-shaped, anteverted, and hypoplastic lobule,
pt short neck.
ba
c
d e
Subject 1 Subject  2
Figure 2 Skull and skeletal abnormalities in two subjects. a, b) brachycephaly in Subject 1 (a) and 2 (b); c) occipital asymmetry in Subject 1;
d) congenital C1-C2 vertebral block; e) accentuation of dorsal kiphosis (arrow) in subject 2.
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ily history is unremarkable.
As an infant, he had difficulty transitioning to solid
foods, with gagging and vomiting. He walked at 13 months.
At 22 months, he had only a few words. By three years,
he was not using any words regularly although he
would use a word for a few days and then stop. With
most activities, he was not able to stay on track, being
quite hyperactive and distractible. His clinical diagno-
sis of autism was confirmed by an assessment using
ADOS at age 2 ½ years. At 13 years of age, his academic
functioning was somewhat variable, with mathematics
being comparable to the skill level of a ten year old, while
the level for other subjects was comparable to an eight
year old.At 22 months, height was above the 50th centile, weight
was below the 10th centile, and OFC was on the 3rd cen-
tile. He had brachycephaly, which had been seen in in-
fancy. The metopic suture, which was open at 7 months,
was closed at 22 months. The left ear was low set, while
the right was dysplastic, prominent, with a thin helix and
an abnormal crural fold. His face appeared to be asym-
metric, due to the right facial nerve palsy. Eye examination
was normal except for right eyelid paralysis, secondary to
the right facial nerve palsy. The remainder of the physical
examination was unremarkable.
Chromosome testing was normal, including FISH at
22q11.2. A CT scan of the brain was normal. Skull radio-
graphs at age 7 months showed a shortened anterior-
posterior diameter relative to width. There was slight
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a little larger and slightly more prominent superiorlaterally
(Figure 2). No obvious sutural stenosis was evident. At
age 14, a C-spine radiograph was normal.
Subject 2
The Subject is a 9 year old boy referred for a genetics
consultation because of delayed milestones and dys-
morphic faces. His parents are non-consanguineous and
he has one healthy sister. His maternal uncle died at the
age of 3 months, of unexplained sudden death. No other
family history of developmental problems or congenital
anomalies was reported. At the age of 3 years, he had
two episodes that raised the suspicion of absence sei-
zures, but the EEG was normal. Delayed development
was noted, especially in language. He spoke few words
with no sentences. Mild motor delay also was described,
with unaided walking starting at 16 months.
At four years, his growth parameters were normal
(weight: 75th percentile; height: 50-75th percentile and
OFC: 50-75th percentile). At five years he had a global
developmental quotient of 53.4 on the Griffiths Mental
Developmental Scale evaluation. His I.Q. at the age of
7 years based on the Wechsler Intelligence Scale was 73
(borderline mental retardation), with a verbal scale of 66
and performance scale of 89. The proband was dysmorphic
with a triangular face, brachycephaly, hypertelorism, up-
slanting palpebral fissures, thin lips, hypertrophic gums, a
pointed chin and short neck (Figure 1). He had abnormal
ears (asymmetric, dysplastic and low-set). The right ear
was small, cup-shaped, anteverted and the lobule was hy-
poplastic. The left ear was bigger than the right, with a
thick helix. Asymmetry of the jaw was noted, with the left
side longer than the right side. His fingers were slightly ta-
pering. Radiographs revealed congenital C1-C2 vertebral
fusion, with accentuation of dorsal kyphosis (Figure 2).
Subject 2 displayed stereotypies, aggressive behavior,
hyperactivity (including jumping if agitated) and atten-
tion deficit. Brain MRI, echocardiogram, abdominal
ultrasound, ophthalmology and ENT examinations were
normal. Radiographs of upper and lower limbs, pelvis
and rib cage did not reveal abnormalities. Chromosome,
FISH for the 22q 11.2 region, molecular testing for Fra-
gile X and metabolic studies (plasma aminoacids, urine
organic acids, CDT, creatine and guanidinoacetic acid in
urine, 7-dehidrocholesterol, lactate, pyruvate and ammo-
nia) were normal.
The clinical description of the two subjects is summa-
rized in Additional file 1: Table S1.
Array CGH
For Subject 1, aCGH revealed a 0.78 Mb de novo dele-
tion at chromosome region 2p13.2-13.3 (72,140,702-
72,924,626), containing 2 genes. Subject 2 had a 4 Mbde novo deletion detected at chromosome region 2p13.1-
p13.3 (chr2:70,748,414-74,840,026), containing 62 genes
(Figure 3A and 3B). The region of overlap between both
cases is 0.78 Mb, located between the 72,140,702-
72,924,626 genomic positions and encompasses the
CYP26B1 and EXOC6B genes.
Functional studies of EXOC6B and notch effector genes
HES1 and RBPJ in subject 1
Significant reduction of RNA expression for all three
genes (EXOC6B, RBPJ and HES1) was detected in lym-
phoblasts from Subject 1 in comparison to three con-
trols (Figure 4A). Protein expression for both HES1 and
RBPJ was also significantly reduced in his lymphoblasts
(Figure 4B and 4C), however, EXOC6B protein level
could not be assessed due to a number of non-specific
bands or a single band of an unexpected size in controls
obtained with three commercial EXOC6 antibodies.
We noted that in control lymphoblasts, the baseline
level of HES1 and RBPJ expression was significantly higher
than EXOC6, possibly due to the fact that EBV viral pro-
tein EBNA2 induces RBPJ expression [36] (Figure 4A). To
eliminate the effect of EBV transformation on RBPJ and
HES expression, whole blood was used from Subject 1
and the controls. Similarly to the lymphoblasts, RNA ex-
pression of EXOC6 and RBPJ was significantly reduced in
the Subject’s whole blood in comparison to a control.
However, HES1 expression was significantly higher in
whole blood of Subject 1 than in the control bloods
(Figure 5). Protein from whole blood was not available
for assessment of RBPJ and HES1 expression levels.
ATRA induction of CYP26B1 expression
EBV transformed lymphoblasts from seven controls and
Subject 1 were treated with 1 μM ATRA for 3 days. To
obtain a quantitative comparison of the ATRA induction
of CYP26B1 in Subject 1 LCLs versus LCLs from con-
trols, the fold difference in CYP26B1 mRNA induction
with ATRA treatment was calculated for Subject 1 and
controls in comparison to the vehicle treated cells.
ATRA induction of CYP26B1 mRNA in LCLs from one
control subject (56.7 ± 3.7 fold) was determined to be an
outlier by Grubb’s test from the other controls and was
excluded from further analysis. The CYP26B1 mRNA
fold-induction from the six remaining control cells was
averaged to show the range in induction in control LCLs
(Figure 6A). CYP26B1 mRNA induction with ATRA
treatment was significantly less in Subject 1 compared to
averaged control cells (1.9 ± 1.5 fold in subject and 12.9 ±
7.3 fold in controls,) (Figure 6A).
The relatively minimal expression of CYP26B1 in
ATRA-treated cells from Subject 1 raised the possibility
of compensatory expression of CYP26A1 to regulate ret-
inoic acid levels. ATRA-treatment resulted in minimal
Subject 2Subject 1
Subject 1
Subject 2
B
A
Figure 3 Array CGH result for Subject 1 and 2. A. Whole genome array profiles in Subject 1 and 2 showing microdeletions of 2p13; B. Gene
content for the microdeletions in Subject 1 and 2.
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agreement with the lack of CYP26A1 induction and
overall low to undetectable expression in blood [18].
CYP26A1 induction was not significantly different in
control LCLs (3.4 ± 3.4 fold) compared to Subject 1
LCLs (0.9 ± 0.9 fold) as shown in Figure 6B. Thus,
CYP26A1 was not induced to a greater extent in re-
sponse to ATRA treatment in cells with a deletion of
CYP26B1. To exclude the possibility that CYP26A1 ex-
pression was higher in Subject 1 cells compared to con-
trol cells prior to ATRA treatment, we compared the
ΔCt values of the vehicle-treated cells and found no differ-
ences (P > 0.05). Hence, it does not appear that CYP26A1
mRNA expression is upregulated to compensate for re-
duced CYP26B1 expression in Subject 1 LCLs. While
upregulation of Cyp26a1 has been observed in Cyp26b1−/−mice at specific developmental stages and tissues during
mouse organogenesis, overall, the expression patterns and
function of Cyp26a1 and Cyp26b1 are considered non-
overlapping during mouse development [37-39].
Discussion
We report a 2p13.1-p13.3 microdeletion observed in two
subjects with clinical effects on the cognitive function (ID
and language delay), behaviour (hyperactivity), and devel-
opment of the craniofacies (facial asymmetry, unusually
shaped and asymmetric ears and brachycephaly). Skull
and vertebral bone abnormalities included slight asym-
metry of the appearance of the orbits and delayed closure
of the metopic suture in Subject 1 and congenital C1-C2
vertebral fusion, and accentuation of dorsal kyphosis in
Subject 2. Previous cases with cytogenetic deletions/
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Figure 4 mRNA and protein expression in Subject 1 and control lymphoblast cells. A. Scatter graph of mRNA expression of EXOC6, RPJB
and HES1in lymphoblasts. Values for EXOC6, RPJB and HES1 mRNA expression were normalized to the corresponding ß-actin mRNA levels. The
results derived from at least three sets of samples and the mean level of each sample is represented in the graph, horizontal bar is an average
value between three controls. The difference between the study sample and the average of the controls has been evaluated by student t-test
(*, p < 0.05; **, P < 0.01). B. RBPJ protein expression. C. HES1 protein expression. C1-C5 indicate control samples from the lymphoblasts, S1
indicate study sample from Subject1. Cell lysates were analyzed by SDS-PAGE and immunoblotting with membrane probed for RBPJ, HES1
and ß-actin, Values for RBPJ and HES1 expression were normalized to the corresponding ß-actin levels. The results derived from at least
three sets of samples and the mean value of each sample is represented in the bar graph. The difference between Subject1 and the
average of three controls has been evaluated by student t-test (*, p < 0.05).
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and the majority had head/facial anomalies, ear and
skeletal abnormalities [1,2].
The overlapping deleted region of our two cases encom-
passes two genes, EXOC6B and CYP26B1, both of which
showed altered function in whole blood and/or LCLs from
Subject 1. The reduced expression of EXOC6B in LCLs
and whole blood could be the cause of the observed
perturbed Notch signaling (i.e. HES1 and RBPJ expression
change), considering the similar effect of EXOC6B knock-
out on Notch signaling in Drosophila.20 The reduction of
RNA expression of EXOC6B and RBPJ was concordant
between LCLs and whole blood, and the expression of the
RBPJ protein also was reduced in Subject 1 lymphoblasts.
However, HES1 had reduced RNA and protein expression
in LCLs and increased RNA expression in whole blood.The discrepancy in the pattern of abnormal expression of
HES1 in different cell types could be due to the difference
in the Notch signaling pathway in lymphoblasts which
contain dedifferentiated B cells vs. whole blood which
contains multiple differentiated cell lineages. Cell-specific
over or underexpression of Hes1 has been reported in dif-
ferent regions of the brain in Rbpj knockout mice [40].
EXOC6B germline mutations or deletions have yet not
been reported in humans. A homozygous mutation in
EXOC6B’s paralogue EXOC6A has been reported in mice
with hemoglobin-deficit (hbd) due to defective iron trans-
port in the endocytosis cycle [41] while haploinsufficiency
of EXOC6A due to a 0.3 Mb microdeletion at 10q23.33,
was reported in a family with nonsyndromic bi- and
unilateral optic nerve aplasia [42]. Interestingly, this
microdeletion also included two CYP genes, CYP26A1
00.5
1
1.5
2
2.5
3
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EXOC6B control
RBPJ patient
RBPJ control
HES1 patient
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Figure 5 mRNA expression of EXOC6, RPJB and HES1 in whole blood of Subject 1 and controls. Values for EXOC6, RPJB and HES1 mRNA
expression in whole blood were normalized to the corresponding ß-actin mRNA levels. The results derived from at least three sets of samples
and the mean level of each sample is represented in the scatter graph, horizontal bar is an average value between three controls. The difference
between subject 1 and the average of the controls has been evaluated by student t-test (*, p < 0.05; **, P < 0.01).
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http://www.ojrd.com/content/8/1/100and CYP26C1. In contrast to very little information on
genetic defects of EXOC6B and their role in disease,
genetic abnormalities of HES1 and RBPJ have been as-
sociated with a number of developmental defects in
vertebrates. Homozygous Hes1 and Rbpj knockout
mice showed severe developmental defects and lethal-
ity [43,44], while Rbpj heterozygous knockout mice
demonstrated learning deficits [29]. In humans, in-
creased expression of HES1 was reported in Down syn-
drome [45] and recent exome sequencing studies
revealed heterozygous mutations in RBPJ and reduced
expression of HES1 in two families with Adams-Oliver
syndrome, associated with congenital cutis aplasia, ter-
minal limb abnormalities (asymmetric shortening ofA
P < 0.05
Figure 6 Induction of CYP26B1 and CYP26A1. A. Fold induction of CYP2
0.05) in the control cells as compared to the Subject 1 (S1) cells with a chr
of CYP26A1 mRNA expression in ATRA-treated cells. There was no significan
cells and Subject 1 cells.the hands and feet in one of the families) and a range
of cognitive functioning (from intellectual disability to
normal) [46].
The deletion of CYP26B1 gene in both our Subjects is
also likely to contribute to their abnormal phenotype, based
on abnormal RA metabolism in Subject 1, as evidenced by
significantly attenuated induction of CYP26B1 expression
with ATRA in comparison to controls. To the best of our
knowledge, there are no reports on the effect of CYP26B1
gene haploinsufficiency in humans. Previously, in two other
families, two different homozygous mutations of CYP26B1
have been reported, resulting in lethality, skeletal and cra-
niofacial abnormalities, including fusion of long bones,
calvarial bone hypopasia and craniosynostosis [16]. In onen.s.B
6B1 mRNA expression. CYP26B1 was induced significantly more (*P <
omosomal deletion of CYP26B1 after treatment with ATRA. B. Induction
t difference (n.s.; P > 0.05) in CYP26A1 induction between the control
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http://www.ojrd.com/content/8/1/100of the families with the hypomorphic mutation, brachyceph-
aly and wide sagittal sutures were noted. The two mutation-
bearing constructs had attenuated ability to metabolize
ATRA (36% and 86%) [16]. In our Subjects, the decreased
RA catabolism and increased sensitivity to RA, as a conse-
quence of CYP26B1 deletion could explain features similar
to those noted by Laue et al. [16] (e.g. brachycephaly for
both subjects, and for Subject 1, the delayed closure of the
metopic suture) and in general compromise the craniofacial,
skeletal development and neuronal functioning. With regard
to the later phenotype, it is of interest that Subject 1 had an
asymmetric crying face as a consequence of a right facial
nerve palsy which previously was associated with RA expos-
ure or early embryonic insult [11,47]. The phenotype of the
subjects is in agreement with developmental effects of
CYP26B1 deletion in experimental animals [37]. CYP26B1
null mice have craniofacial abnormalities, exhibit abnormal
ear development and other bone and cartilage deformities
[13]. Interestingly, the truncated limbs observed in
CYP26B1−/− mice were absent in the patients. Similarly, in
the zebrafish CYP26B1 deletion has been shown to re-
sult in overall defective craniofacial cartilage develop-
ment with smaller head, severely decreased number of
vagal branchiomotor neurons and defective or absent
jaw cartilage [48].
It is intriguing to note the lethal phenotype in two
subjects reported by Laue et al. [16] due to homozygous
mutations of CYP26B1 in comparison to the survival
and developmental abnormalities in our subjects with
hemizygous CYP26B1 deletion. The presence of one
normal copy of the gene in each of our subjects and the
efficiencies of the other two remaining RA catabolizing
CYP26 genes (CYP26A1 and CYP26C1), possible com-
pensatory changes in other proteins known to regulate
retinoic acid, such as RALDH [8,49,50] and environmen-
tal influences, such as diet and pharmacological treat-
ment, [6,51] all could have an effect on the phenotypes.
Phenotypic variability also was noted for carriers of
CYP26A1, CYP26C1 and EXOC6A deletions within one
family [42], ranging from normal vision, to uni- and bi-
lateral optic nerve hypoplasia and variable levels of cog-
nitive functioning (normal to impaired).
The combined effect of deletion of both EXOC6B and
CYP26B1 on Notch and RA signaling, and consequently
the phenotype, also should be considered in our sub-
jects. Interaction of RA and Notch signaling in deter-
mination of left/right asymmetry and segmentation has
been reported by Echeverri and Oates [52] who noted
the requirement of Rbpj function for expression of RA
catabolizing enzyme Cyp26a1 which in turn, is needed
for left/right symmetric cyclic gene expression. Vermot
et al. [53] demonstrated that reduced levels of RA were
associated with abnormal Hes1 expression and asym-
metry in mouse embryos, while Castella et al. [54]showed that addition of RA raises the level of HES1 pro-
tein expression in in vitro cell culture.
Subject 2 had additional phenotypic features not noted
in Subject 1, which might be explained by the larger size
of the 2p13.1-13.3 deletion, interaction of its integral
genes and genetic background. For example, seizure-like
episodes were not noted in Subject 1, but were present
in Subject 2 and a Decipher subject, # 257412, with de-
velopmental delay, whose deletion of 2p12-13.3 was
6.8 Mb (70,889,254-77,746,500), and his features in-
cluded coarse faces, a flat malar region, myopathic hypo-
tonia and prominent ears. The cervical fusion and spine
abnormality are unique for Subject 2 and are of interest,
considering the report of a subject with Klippel-Fiel
anomaly, who had a balanced inversion involving
chromosome 2p13 and congenital fusion of the cervical
spine, impairment of hearing, psychomotor retardation,
speech limitation, short stature, spinal asymmetry and
scoliosis [3]. The genes disrupted/deleted by this chromo-
some rearrangement are unknown, however, it was specu-
lated that CYP26B1 was involved based on the similar
vertebral phenotype observed in zebrafish with Cyp26b1
mutations [4].
Our report is unique as it provides a new insight into
the phenotypic and functional consequences of hemizy-
gous deletion of two genes implicated in Notch and Ret-
inoic acid signaling. It also supports the previous cell
line and animal model based observation of exocyst role
in Notch signaling. Further studies of exocyst complex
function in patient cells would be of interest for under-
standing of its role in human disease.
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